当前位置： SCI文献检索 > Clinical Colorectal Cancer期刊下所有文献 > Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.

Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.

Abstract：

:Replacing infusional 5-fluorouracil (5-FU) leucovorin (LV) with oral capecitabine would be more convenient to patients, because it would lead to reduced hospital chair time and infusion-related toxicities. Previous trials with oral capecitabine-based regimens (other than XELOX [capecitabine/oxaliplatin]) have failed to demonstrate the equivalent efficacy of capecitabine based regimens to various 5-FU/oxaliplatin regimens (nonstandard FOLFOX [5-FU/LV/oxaliplatin] combinations); of note, these trials did not use the XELOX and standard FOLFOX regimens. An international phase III trial (NO16966) was initiated to demonstrate the noninferiority of XELOX to FOLFOX4 for the first-line treatment of metastatic colorectal cancer. The protocol was later amended to compare bevacizumab and chemotherapy versus placebo and chemotherapy. The efficacy data showed that XELOX was as effective as FOLFOX4 (progression-free survival [PPS; intent-to-treat population]: hazard ratio [HR], 1.04; 97.5% confidence interval, 0.93-1.16). Also, bevacizumab/chemotherapy(pooled with XELOX or FOLFOX) significantly prolonged PPS (HR 0.83; p=0.0023) compared with placebo and chemotherapy (XELOX/FOLFOX). In subgroup analysis, the addition of bevacizumab to XELOX (9.3 months vs. 7.4 months. HR.0.77; P=0.0026) and FOLFOX4(9.4 months vs. 8.6 months; HR, 0.89; P = 0.1871) prolonged PFS compared with respective placebo arms; however, it did not show statistical significance with the FOLFOX4 regimen. The adverse events were manageable and comparable between treatment arms.

journal_name

Clin Colorectal Cancer

journal_title

Clinical colorectal cancer

authors

Tyagi P,Grothey A

doi

10.3816/CCC.2006.n.044

subject

Has Abstract

pub_date

2006-11-01 00:00:00

pages

261-4

issue

4

eissn

1533-0028

issn

1938-0674

pii

S1533-0028(11)70472-8

journal_volume

6

pub_type

杂志文章

相关文献

Clinical Colorectal Cancer文献大全
  • Outcome of Molecular Targeted Agents Plus Chemotherapy for Second-Line Therapy of Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Trials.

    abstract：INTRODUCTION:The aim of this study was to evaluate the efficacy and toxicity of molecular targeted agents plus chemotherapy compared with chemotherapy alone as second-line therapy for patients with metastatic colorectal cancer (mCRC). MATERIALS AND METHODS:We identified randomized controlled trials that compared molec...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.clcc.2016.03.005

    authors： Pei X,Liu Y,Sun L,Zhang J,Fang Y,Liao X,Liu J,Zhang C,Yin T

    更新日期：2016-12-01 00:00:00

  • Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age.

    abstract：BACKGROUND:Screening protocols for colorectal cancer are broadly recommended and effective in reducing mortality. However, populations from different age groups can harbor distinct pathologic and molecular profiles that can also be influenced by screening and polyp resection, especially in older ages. PATIENTS AND MET...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2020.06.004

    authors： Pereira AAL,Fernandes GDS,Braga GTP,Marchetti KR,Mascarenhas CDC,Gumz B,Crosara M,Dib L,Girardi D,Barrichello A,Seidler H

    更新日期：2020-12-01 00:00:00

  • Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.

    abstract：BACKGROUND:In this study, the maximum tolerated dose and toxicity profile of FOLFIRI (infusional fluorouracil [5-FU]/leucovorin/irinotecan) plus gefitinib (an oral inhibitor of the epidermal growth factor receptor) were evaluated as first-line therapy in patients with metastatic colorectal cancer. PATIENTS AND METHODS...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2006.n.037

    authors： Wolpin BM,Clark JW,Meyerhardt JA,Earle CC,Ryan DP,Enzinger PC,Zhu AX,Blaszkowsky L,Battu S,Fuchs CS

    更新日期：2006-09-01 00:00:00

  • Locoregional strategies for colorectal hepatic metastases.

    abstract：:Hepatic colorectal metastases present a challenging problem in patients with recurrent colorectal cancer. Twenty percent of patients with recurrence will have liver metastases as a component of their disease, and only 10% of these patients will have isolated liver metastases that are resectable. Although systemic chem...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CCC.2003.n.010

    authors： Meyers MO,Sasson AR,Sigurdson ER

    更新日期：2003-05-01 00:00:00

  • Rising Proportion of Young Individuals With Rectal and Colon Cancer.

    abstract：BACKGROUND:Recent trends have identified increasing number of young individuals with rectal and colon cancers. These individuals, who are younger than 50 years old, in most instances would not meet screening guidelines. We aimed to report the characteristics and trend of the rising proportion of young individuals being...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2018.10.002

    authors： Kasi PM,Shahjehan F,Cochuyt JJ,Li Z,Colibaseanu DT,Merchea A

    更新日期：2019-03-01 00:00:00

  • Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.

    abstract：BACKGROUND:The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation (ICECREAM) study assessed the efficacy of cetuximab monotherapy compared with cetuximab combined with chemotherapy for quadruple wild-type (KRAS, NRAS, BRAF, or P13KCA exon 20) metastatic colorectal cancer. PATIENTS AND METHODS:Patients w...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clcc.2018.06.002

    authors： Shapiro JD,Thavaneswaran S,Underhill CR,Robledo KP,Karapetis CS,Day FL,Nott LM,Jefford M,Chantrill LA,Pavlakis N,Tebbutt NC,Price TJ,Khasraw M,Van Hazel GA,Waring PM,Tejpar S,Simes J,Gebski VJ,Desai J,Segelov E

    更新日期：2018-12-01 00:00:00

  • Circulating endothelial cells and their subpopulations: role as predictive biomarkers in antiangiogenic therapy for colorectal cancer.

    abstract：:Several anticancer therapies have been developed to block angiogenesis, a key mechanism in tumor growth and metastasis. The predominantly cytostatic action of these compounds makes an assessment of their clinical activities inadequate if based only on the reduction of the tumor dimensions, as this may not reflect thei...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2014.12.002

    authors： Manzoni M,Comolli G,Torchio M,Mazzini G,Danova M

    更新日期：2015-03-01 00:00:00

  • COVID-19 and the Global Impact on Colorectal Practice and Surgery.

    abstract：BACKGROUND:The novel severe acute respiratory syndrome coronavirus 2 virus that emerged in December 2019 causing coronavirus disease 2019 (COVID-19) has led to the sudden national reorganization of health care systems and changes in the delivery of health care globally. The purpose of our study was to use a survey to a...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2020.05.011

    authors： Nunoo-Mensah JW,Rizk M,Caushaj PF,Giordano P,Fortunato R,Dulskas A,Bugra D,da Costa Pereira JM,Escalante R,Koda K,Samalavicius NE,Maeda K,Chun HK,ISUCRS COVID-19 Participating Investigator Group.

    更新日期：2020-09-01 00:00:00

  • Laparoscopic radical correction combined with extensive lymphadenectomy and pelvic autonomic nerve preservation for mid-to-low rectal cancer.

    abstract：OBJECTIVE:The purposes of this study were to confirm the definite metastasis and micrometastasis rate of upward and lateral lymph nodes of mid-to-low rectal cancer at stage II and stage III, and to evaluate the feasibility and safety of laparoscopic radical correction combined with extensive lymphadenectomy and pelvic ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2011.03.025

    authors： Liu T,Zhang C,Yu P,Chen J,Zeng D,Gan L,Lv W,Liu L,Yan X

    更新日期：2011-09-01 00:00:00

  • Multidisciplinary perspective on the management of appendiceal adenocarcinoma: case review of 10 patients from a university hospital and current considerations.

    abstract：BACKGROUND:Adenocarcinoma of the vermiform appendix is rare. It constitutes less than 0.5% of all gastrointestinal malignancies. Pathologically, appendiceal neoplasms are categorized into various subtypes depending on cell lineage. PATIENTS AND METHODS:We considered a case series of appendiceal invasive adenocarcinoma...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2014.11.003

    authors： Bunni J,Arnold D,Shelley-Fraser G,Shabbir J

    更新日期：2015-03-01 00:00:00

  • Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer.

    abstract：BACKGROUND:Initial treatment with either neoadjuvant chemoradiation (CRT) or induction FOLFOX (5-Fluorouracil, leucovorin, and oxaliplatin) chemotherapy followed by CRT is considered standard treatment for locally advanced rectal cancer. We compared patient-reported outcomes (PRO) during CRT in patients who had receive...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2019.04.001

    authors： Ng SY,Colborn KL,Cambridge L,Cercek A,Reidy-Lagunes DL,Segal N,Stadler Z,Saltz LB,Paty PB,Guillem J,Weiser MR,Nash G,Garcia-Aguilar J,Goodman KA

    更新日期：2019-09-01 00:00:00

  • Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.

    abstract：:Colorectal cancer (CRC) is the second most common cause of cancer-related death in the United States. Despite excellent prognosis for early stage disease, 5-year survival rates in metastatic disease remain low. A small subset of CRC is defined by a deficiency in mismatch repair (dMMR) resulting in high levels of micro...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2020.02.002

    authors： Thomas J,Leal A,Overman MJ

    更新日期：2020-06-01 00:00:00

  • Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study.

    abstract：INTRODUCTION:Hepatic arterial infusion chemotherapy (HAIC) is a treatment used for liver metastases (LM) of colorectal cancer (CRC). Because of its technical conditions, it has been used in only a few experienced centers in France. Our aim was to evaluate its feasibility, efficacy and tolerance in 4 centers. METHODS:C...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clcc.2017.03.003

    authors： Lim A,Le Sourd S,Senellart H,Luet D,Douane F,Perret C,Bouvier A,Métairie S,Cauchin E,Rougier P,Matysiak-Budnik T,Touchefeu Y

    更新日期：2017-12-01 00:00:00

  • A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.

    abstract：PURPOSE:Capecitabine has shown similar efficacy to 5-fluorouracil (5-FU); a regimen containing 2 weeks of capecitabine/oxaliplatin (CapOx) has demonstrated noninferiority to infusional 5-FU/oxaliplatin/leucovorin (FOLFOX) for the treatment of metastatic colorectal cancer (mCRC). This phase II study explores the efficac...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.3816/CCC.2010.n.021

    authors： Lubner SJ,Loconte NK,Holen KD,Schelman W,Thomas JP,Jumonville A,Eickhoff JC,Seo S,Mulkerin DL

    更新日期：2010-07-01 00:00:00

  • Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.

    abstract：:To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies for metastatic colorectal cancer (mCRC), we performed a systematic review of published cost-effectiveness analyses. We identified 14 papers that fulfilled our search criteria and revealed varying levels of value among current trea...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2015.10.002

    authors： Goldstein DA,Zeichner SB,Bartnik CM,Neustadter E,Flowers CR

    更新日期：2016-03-01 00:00:00

  • AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.

    abstract：BACKGROUND:The efficacy and safety of the FOLFIRI (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) regimen combined with aflibercept has not been studied in the first-line management of patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS:In the context of a prospective single-arm trial (NC...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clcc.2018.06.003

    authors： Pentheroudakis G,Kotoula V,Koliou GA,Karavasilis V,Samantas E,Aravantinos G,Kalogeropoulou L,Souglakos I,Kentepozidis N,Koumakis G,Sgouros J,Zarkavelis G,Efstratiou I,Laschos K,Petraki C,Tikas I,Poulios C,Voutsina A,G

    更新日期：2018-12-01 00:00:00

  • Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value?

    abstract：:As new improvements in the treatment of colorectal cancer have become available, it has become important to understand the benefits of new therapies or the deleterious effects stemming from the increased risk of toxicity. In particular, a more rational approach to adjuvant chemotherapy for patients with stage II/III d...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/ccc.2006.n.019

    authors： Funaioli C,Pinto C,Mutri V,Di Fabio F,Ceccarelli C,Martoni AA

    更新日期：2006-05-01 00:00:00

  • Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.

    abstract：:Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal cancer of teh gastrointestinal tract. They are characterized by the expression of KIT. Therapeutically, metastatic GISTs are effectively treated by imatinib, a tyrosine kinase inhibitor (TKI) with activity against KIT and platelet-derived growth f...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/ccc.2006.s.005

    authors： von Mehren M

    更新日期：2006-11-01 00:00:00

  • Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System.

    abstract：BACKGROUND:Metastatic colorectal cancer (CRC) outcomes continue to improve, but they vary significantly by race and ethnicity. We hypothesize that these disparities arise from unequal access to care. MATERIALS AND METHODS:The Harris Health System (HHS) is an integrated health delivery network that provides medical car...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2019.09.002

    authors： Lau-Min K,Prakash P,Jo E,Thrift AP,Hilsenbeck S,Musher BL

    更新日期：2020-06-01 00:00:00

  • Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.

    abstract：UNLABELLED:Two identical randomized controlled trials designed to optimize adjuvant treatment of colon cancer (CC) (n =855) and rectal cancer (RC) (n = 796) were performed. Long-term evaluation confirmed that the addition of folinic acid (FA) to 5-fluorouracil (5-FU) improved 7-year overall survival (OS) in CC but not ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clcc.2012.07.005

    authors： Kornmann M,Staib L,Wiegel T,Kron M,Henne-Bruns D,Link KH,Formentini A,Study Group Oncology of Gastrointestinal Tumors (FOGT).

    更新日期：2013-03-01 00:00:00

  • Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit.

    abstract：BACKGROUND:The optimal therapeutic strategy for metastatic colorectal cancer patients is still a matter of debate. There are no prognostic variables indicating how many lines individual patients ought to receive, and whether later lines could be effective even when earlier ones were not. PATIENTS AND METHODS:We retros...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2017.03.019

    authors： Tampellini M,Di Maio M,Baratelli C,Anania L,Brizzi MP,Sonetto C,La Salvia A,Scagliotti GV

    更新日期：2017-12-01 00:00:00

  • Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.

    abstract：BACKGROUND:Treatment sequencing for patients with refractory metastatic colorectal cancer (mCRC) has been highly debated. The thymidine-based nucleoside trifluridine/tipiracil (TAS-102) and the multikinase inhibitor regorafenib have demonstrated clinical benefits in randomized phase III trials compared with placebo. Ho...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2018.05.012

    authors： Unseld M,Drimmel M,Siebenhüner A,Gleiss A,Bianconi D,Kieler M,Scheithauer W,Winder T,Prager GW

    更新日期：2018-12-01 00:00:00

  • Conversion to Resection in Patients Receiving Systemic Chemotherapy for Unresectable and/or Metastatic Colorectal Cancer-Predictive Factors and Prognosis.

    abstract：BACKGROUND:Systemic chemotherapy increases the possibility of resection in patients with initially unresectable colorectal cancer (CRC), especially patients with hepatic metastasis. However, the predictive factors and prognosis of conversion to resection after chemotherapy in patients with various organ metastases rema...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2017.10.002

    authors： Nozawa H,Ishihara S,Kawai K,Hata K,Kiyomatsu T,Tanaka T,Nishikawa T,Otani K,Yasuda K,Sasaki K,Kaneko M,Murono K

    更新日期：2018-03-01 00:00:00

  • Spindle Assembly Checkpoint as a Potential Target in Colorectal Cancer: Current Status and Future Perspectives.

    abstract：:Colorectal cancer (CRC), one of the most common malignancies worldwide, is often diagnosed at an advanced stage, and resistance to chemotherapeutic and existing targeted therapy is a major obstacle to its successful treatment. New targets that offer alternative clinical options are therefore urgently needed. Recently,...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2016.06.006

    authors： Diogo V,Teixeira J,Silva PM,Bousbaa H

    更新日期：2017-03-01 00:00:00

  • Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancer.

    abstract：:Epidermal growth factor receptor (EGFR) has been validated as an important target in the treatment of metastatic colorectal cancer (mCRC). While initial studies focused on the treatment of disease that was refractory to available chemotherapy agents, 2 recent themes have emerged: the use of KRAS mutation status to sel...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CCC.2010.s.006

    authors： Stein S,Cohen DJ,Hochster HS

    更新日期：2010-06-01 00:00:00

  • Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications.

    abstract：BACKGROUND:Gemcitabine-related pneumonitis (GRP) has been reported relatively frequently for pancreas cancer in the literature; however, underlying risk factors and optimal management remain to be defined. We studied a cohort of patients with GRP and investigated potential predisposing factors in pancreatic cancer pati...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2015.08.003

    authors： Sahin IH,Geyer AI,Kelly DW,O'Reilly EM

    更新日期：2016-03-01 00:00:00

  • Patients with colorectal and renal cell carcinoma diagnoses appear to be at risk for additional malignancies.

    abstract：UNLABELLED:Patients with colorectal cancer (CRC) and renal cell carcinoma (RCC) may be at risk for additional primary malignancies. A review of 101 patients with these concurrent diagnoses was performed. Forty-two percent of patients had 1 or more additional malignancies; none appeared to be associated with Lynch syndr...

    journal_title：Clinical colorectal cancer

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.clcc.2012.07.004

    authors： Steinhagen E,Moore HG,Lee-Kong SA,Shia J,Eaton A,Markowitz AJ,Russo P,Guillem JG

    更新日期：2013-03-01 00:00:00

  • Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.

    abstract：BACKGROUND:The safety of bevacizumab in older mCRC patients is poorly understood. The purpose of this analysis was to determine the prevalence, incidence, and risk factors for treatment-related AEs in older bevacizumab recipients. PATIENTS AND METHODS:Patients age ≥65 were identified from SEER-Medicare and categorized...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章

    doi：10.1016/j.clcc.2012.11.004

    authors： Shankaran V,Mummy D,Koepl L,Blough D,Yim YM,Yu E,Ramsey S

    更新日期：2013-09-01 00:00:00

  • The Role of the Gut Microbiome in Colorectal Cancer: Where Are We? Where Are We Going?

    abstract：:Microbiome (microbiota) is a community of all microorganisms inhabiting a specific site of the body, including pathogens, which distinguishes it from the physiological microflora. Intestinal dysbiosis plays a key role in the development of colorectal cancer. In the process of carcinogenesis, inflammation, immune respo...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2019.07.006

    authors： Wieczorska K,Stolarek M,Stec R

    更新日期：2020-03-01 00:00:00

  • Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.

    abstract：:Significant advances have been made with respect to our understanding of the critical role of agents targeting angiogenic pathways in the treatment of metastatic colorectal cancer (mCRC). The approval of 3 agents that target angiogenic signaling, bevacizumab, ziv-aflibercept, and regorafenib, provides strong evidence ...

    journal_title：Clinical colorectal cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clcc.2014.02.001

    authors： Lee JJ,Chu E

    更新日期：2014-09-01 00:00:00